Navigation Links
NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update
Date:3/31/2008

HUBBARD, Ohio, March 31 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (OTC: NNLX - News) a nano-biotechnology company is pleased to provide the following updates on company events:

NanoLogix personnel are manning a booth and presenting at the National Hydrogen Association Expo in Sacramento this week, with the company being represented by William Hartman and Chris Novak. Mr. Hartman will be presenting in the Exhibition Hall today, March 31, from 2:00-2:30 pm, on "Biohydrogen and Electricity Production from Waste Water".

Company CEO Bret Barnhizer was Marlene Bourne's guest on The Bourne Report March 16, on the topic of Hydrogen Power. The interview provides updates on hydrogen bioreactor operations. Access: http://www.bournereport.com/radio.php

Work on BNC and BNP development for fast microorganism detection is proceeding at a rapid pace, with a new patent application filed in March and positive developments with both the Departments of Defense and Homeland Security in late February.

Director and Management changes: Dr. Robert Ollar and John Chatterton have joined the Board of Directors. Dr. Ollar is cofounder of NanoLogix (as Infectech), the primary author of the majority of the company's granted patents, and returns to the company after a six year hiatus. Mr. Chatterton is former co-host of the History Channel series, Deep Sea Detectives, and is one of the world's most accomplished and well known underwater explorers. David Barnhizer has joined the company as General Counsel, bringing to the company nearly forty years of legal expertise. Detailed director and management team information can be accessed at: http://www.nanologixinc.com/index-2.html

General Counsel David Barnhizer stated: "NNLX is poised to make a significant move forward under its new board of directors and management team headed by CEO and Board Chairman Bret Barnhizer and complemented by a reformed and greatly strengthened board of directors. A skilled and knowledgeable team of professionals whose members are fully dedicated to the advancement of NanoLogix has been put into place. As NNLX General Counsel I am extremely pleased to be associated with a group of professionals committed to the building of an exceptional company whose patented technologies are on the cutting edge of hydrogen energy extraction from industrial and commercial wastes, as well as diagnostic tools that are drawing the attention of governmental and commercial institutions."

The company has accepted the resignations of directors Hartman, Allan, and Cavallo from all positions held. Mr. Hartman will continue to provide business consulting services to NanoLogix.

About NanoLogix, Inc.

NanoLogix is a leading innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes. The Company has 31 granted Patents and multiple Patents Pending for bioreactor- based Hydrogen Production, revolutionary rapid medical testing technologies, and bioremediation. Information on NanoLogix is available at http://www.nanologixinc.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Contact:

Investor Relations

Bret Barnhizer, CEO

Telephone: 330-534-0800

E-mail: Bret@nanologixinc.com


'/>"/>
SOURCE NanoLogix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. National Public Radio (NPR) Features Broadcast Articles on NanoLogix Hydrogen Bioreactor Operation at Welchs Foods
2. NanoLogixs Hydrogen-From-Waste Technology at Welchs Foods Featured on Environmental Radio Program
3. NanoLogix, Inc. Makes Stock Pick List
4. NanoLogix Inc. Sets Date for Annual Shareholder Meeting and Provides Shareholder Update
5. NanoLogix Inc. to Present at EBW Expo & Conference 2007
6. NanoLogix Inc. Announces Historical First in Energy Generation With Bioreactor-Produced Hydrogen at Welchs
7. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
10. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
11. Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... The Global Market for Bioproducts Should Reach $714.6 Billion by ... 8.9%, This research report quantifies the two ... segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite materials, ...
(Date:3/23/2017)... Mass. , March 23, 2017 /PRNewswire/ ... partner to global in vitro diagnostics manufacturers ... of the industry,s first multiplexed Inherited ... disease testing by next-generation sequencing (NGS). The ... were developed with input from industry experts ...
(Date:3/23/2017)... PARK, Calif., March 23, 2017  BioPharmX Corporation ... products for the dermatology market, today reported financial ... 31, 2017, and will provide an update on ... the year. "We are pleased to ... year for BioPharmX," said President Anja Krammer. "We ...
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
Breaking Biology Technology:
(Date:2/21/2017)... 2017 Der weltweite Biobanking-Sektor wird ... einem Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen ... gilt, um diese Prognose zu realisieren. ... Zu den ... finanziellen Mittel für die Biobank, die Implementierung Zeit sparender ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
Breaking Biology News(10 mins):